RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
+3.35%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 31.0K | 31.0K | — | — | — |
| Gross Profit | (31.0K) | (31.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 53.8M | 53.8M | 61.5M | 55.7M | 43.8M |
| SG&A Expense | 29.3M | 29.2M | 18.4M | 14.7M | 12.2M |
| General & Admin Expense | 29.1M | 29.2M | 18.4M | 14.7M | 12.2M |
| Selling & Marketing Expense | 167.0K | — | — | — | — |
| Other Expenses | (120.0K) | — | — | — | — |
| Total Operating Expenses | 82.9M | 83.0M | 79.9M | 70.4M | 56.0M |
| Cost and Expenses | 83.0M | 83.0M | 79.9M | 70.4M | 56.0M |
| Operating Income (EBIT) | (83.0M) | (83.0M) | (79.9M) | (70.4M) | (56.0M) |
| Non-Operating | |||||
| Interest Income | 4.9M | 4.9M | 5.5M | 4.9M | 4.2M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.9M | 4.9M | 5.5M | 4.9M | 4.2M |
| Other Non-Op Income/Expense | 5.4M | 5.4M | 5.5M | 2.0M | 4.2M |
| Non-Operating Income (excl Interest) | (4.3M) | — | (5.5M) | (2.0M) | (4.2M) |
| EBT (Pre-Tax Income) | (77.6M) | (77.6M) | (74.4M) | (68.5M) | (51.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (77.6M) | (77.6M) | (74.4M) | (68.5M) | (51.8M) |
| Earnings from Cont. Ops | (77.6M) | (77.6M) | (74.4M) | (68.5M) | (51.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (77.6M) | (77.6M) | (74.4M) | (68.5M) | (51.8M) |
| Per Share | |||||
| Basic EPS | ($0.76) | ($0.75) | ($0.98) | ($1.33) | ($1.01) |
| Diluted EPS | ($0.76) | ($0.75) | ($0.98) | ($1.33) | ($1.01) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 104.5M | 103.9M | 76.0M | 51.5M | 51.2M |
| Diluted Shares Outstanding | 104.5M | 103.9M | 76.0M | 51.5M | 51.2M |
| Profitability Metrics | |||||
| EBITDA | (78.6M) | (83.0M) | (74.4M) | (68.4M) | (51.8M) |
| D&A | 31.0K | 31.0K | 31.0K | 36.0K | 30.0K |
| EBIT | (78.7M) | (83.0M) | (74.4M) | (68.5M) | (51.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026